Fetzima (levomilnacipran) is not indicated for the treatment of pain [1]. It is approved for the treatment of major depressive disorder (MDD) in adults [2].
Why is Fetzima used for depression?
Fetzima is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain [3]. These neurotransmitters play a role in regulating mood, and their increased availability is thought to help alleviate symptoms of depression [3].
What other conditions might Fetzima be used for off-label?
While Fetzima is specifically approved for MDD, healthcare providers may sometimes prescribe medications off-label for conditions not listed on the drug's label if they believe it could be beneficial to the patient [4]. However, there is no established off-label use of Fetzima for pain management in the provided information.
How does Fetzima compare to other antidepressants?
As an SNRI, Fetzima belongs to a class of antidepressants that also includes medications like duloxetine (Cymbalta) and venlafaxine (Effexor XR) [5]. These medications differ in their specific chemical structures, pharmacokinetic profiles, and potential side effect profiles [5]. Fetzima is a levo-isomer of milnacipran, which is approved for fibromyalgia in some regions, but Fetzima's indication is for MDD [2][6].
What are the potential side effects of Fetzima?
Common side effects of Fetzima can include nausea, constipation, increased sweating, insomnia, and increased heart rate [2]. More serious side effects are possible and should be discussed with a healthcare provider [2].
When does the patent for Fetzima expire?
Information on Fetzima's patent expiry is available through specialized resources. For detailed patent information, including expiry dates and any potential challenges, DrugPatentWatch.com is a source that tracks such data [7].